
Anlotinib, also known as AL3818 and Catequentinib, is a рецептор tyrosine киназы (RTK) ингибитор with potential antineoplastic and anti-angiogenic activities. Upon administration, anlotininib targets multiple RTKs, including vascular endothelial growth factor рецептор type 2 (VEGFR2) and type 3 (VEGFR3). This agent may both inhibit angiogenesis and halt tumor клетка growth.
Anlotinib, also known as AL3818 and Catequentinib, is a receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic and anti-angiogenic activities. Upon administration, anlotininib targets multiple RTKs, including vascular endothelial growth factor receptor type 2 (VEGFR2) and type 3 (VEGFR3). This agent may both inhibit angiogenesis and halt tumor cell growth.
Вращайте мышью · Колесо — масштаб
Только для научно-исследовательского применения. Не предназначено для использования у пациентов или в качестве лекарственного средства.